Sucampo Pharmaceuticals — Q2 2015 Earnings Presentation
24 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 5, 2015
Slide 1: Q2 2015 Corporate Update and Financial Results
Q2 2015 Corporate Update and Financial Results August 5, 2015 $ SUCAMPO ‘The Science of Innovation
Slide 2: Introductions and Forward-Looking Statements
luctions and Forward= ig Statements Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications ¢ 9 SUCAMPO ‘The Science of Innovation
Slide 3: Agenda
Agenda | eae eon ornare ooking Silvia Taylor Corporate Update Peter Greenleaf | Pipeline Update : Peter Kiener, D. Phil Financial Performance Andrew Smith Closing Remarks Peter Greenleaf $F SUCANES sansa
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, ‘These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ
Slide 5: Peter Greenleaf, Chief Executive Officer
15 Corporate Update Peter Greenleaf Chief Executive Officer § SUCAMPO ‘The Science of Innovation .S
Slide 6: Revenue Growth, Earnings Growth
Revenue Growth Earnings Growth $9.3 $9.6 $6.4 $2.3 — $1.6 $0.6 3-1 414 at Otis 0414 ans ats 02-14 C215 1 Product Royalty/Product Sales «Other, including milestones Raising 2015 Guidance | + $30 - $35M for net income ¢ 6 + $0.65 - $0.75 per diluted share 3 SUCAMPO — a ~ ‘The Science of Innovation In
Slide 7: Continued Financial Performance
Continued Financial Performance Significant gains drove strong financial performance + Overall revenue grew 45% + Product royalty revenue grew 16% + Product sales revenue grew 92% Net income and EPS + Net income: $9.6M, increased 495% + EPS: $0.21, increased 425% SUCAMPO ‘The Science of Innovation w
Slide 8: U.S. AMITIZA Performance
U.S. AMITIZA Performance Takeda AMITIZA net sales* + Increased 15% to $88.2M Sucampo AMITIZA revenue + Royalty revenue grew 16% AMITIZA prescriptions + 363,000 TRx’s, increased 10% + New Rx grew 13% + Highest quarter of prescriptions since launch Constipation category grew 7% SUCAMPO . “Reported by
Slide 9: Japan AMITIZA Performance
Japan AMITIZA Performance Sucampo revenue + Sales grew 101% to $14.5M Mylan committed to brand growth * Significant detailing levels * Brand “launch” ww SUCAMPO id ‘The Science of Innovation
Slide 10: AMITIZA Globally
AMITIZA Globally Asia + — Entered into exclusive agreement with Harbin Gloria Pharmaceuticals for AMITIZA in China + — June: Acceptance of IND for AMITIZA in CIC by the CFDA + Recognized $1.5M upfront payment Europe + Austria, Germany and Italy issued NMA + Ireland, Luxembourg, the Netherlands and B
Slide 11: Evaluation of External Assets
ion of External Assets Assessment of external programs ongoing Complement existing product pipeline Accretive in short term Leverage current skills and Specialty focus experience $ sucampo " ‘The Science of Innovation
Slide 12: Pipeline Update
line Update Peter Kiener, D. Phil Chief Scientific Officer § SUCAMPO ‘The Science of Innovation .S
Slide 13: Pediatric Functional Constipation (PFC) 6-17 Years
Pediatric Functional Constipation (PFC) 6-17 Years Enrollment continues at development sites across the U.S., Europe in single pivotal clinical trial Data expected in 1H16 Expect to file NDA in 2H16 SUCAMPO e ‘The Science of Innovation ww
Slide 14: AMITIZA Alternate Formulation & PFC 6 Months-6 Years
AMITIZA Alternate Formulation & PFC 6 Mos=6;Yrs Expect to initiate P3 study in adult CIC patients in 2H15 + Data expected in 1H16 + Expect to file NDA in 2H16 Single pivotal trial in children (6 months-6 years) to commence once alternate formulation is available + Expect to initiate in 1H16 + Expect
Slide 15: Cobiprostone for PPI-Refractory NERD/GERD
Cobiprostone for PPI-Refractory NERD/GERD Phase 2 study underway + 140-person randomized, double-blind, placebo-controlled, multicenter study * 14 week study comprising a total of 8 weeks of treatment Expect to announce top-line data in 1H16 ww SUCAMPO i ‘The Science of Innovation
Slide 16: Cobiprostone for Oral Mucositis
Cobiprostone for Oral Mucositis U.S. FDA Fast Track Designation granted in May FDA accepted IND application for P2a clinical trial Expect dosing of patients soon SUCAMPO se ‘The Science of Innovation ww
Slide 17: Financial Performance Update
rformance Update Andrew Smith Chief Financial Officer § SUCAMPO ‘The Science of Innovation .S
Slide 18: Significant Non-GAAP Earnings Growth
Significant Non-GAAP Earnings Growth Q2-14 Q2-15 EBITDAS $ sucAMPO "8 In millions of USD The Science of Innovation
Slide 19: Cost of Goods Sold, R&D, G&A and S&M Expenses
$7.3 $7.1 | Q2-14 Q2-15 Q2-14 Q2-15 Q2-14 Q2-15 Q2-14 Q2-15 Cost of Goods Sold R&D Expenses G&A Expenses S&M Expenses - $ sucAMPO 9 In millions of USD ‘The Science of Innovation
Slide 20: Improvements in Effective Tax Rate
Improvements in Effective Tax Rate 53% Q2-14 = Q2-15 ¢ 20 ? SUCAMPO ‘The Science of Innovation
Slide 21: Strong Balance Sheet
Strong Balance Sheet | item | asof 063015 | Change | As of 06/30 Cash, Cash Equivalents, $127.7 $24.1M $103.6M Restricted Cash and Investments. Notes Payable ($21.7M) $27.8M ($49.5M) Cash, Cash Equivalents, $106.0M $51.9M $54.1M Restricted Cash and Investments, net of Debt Six Months ix Months Endin
Slide 22: Peter Greenleaf, Chief Executive Officer
Peter Greenleaf Chief Executive Officer § SUCAMPO ‘The Science of Innovation .S
Slide 23: Continuing to Make Progress on 2015 Expectations
Continuing to Make Progress on 2015 Expectations ¥ Outstanding financial performance v Advancing our pipeline v Evaluating opportunities for long-term growth SUCAMPO 2 ‘The Science of Innovation ww
Slide 24: ? SUCAMPO
¢ 24 ? SUCAMPO ‘The Science of Innovation
Sucampo Pharmaceuticals — Q2 2015 Earnings Presentation on 6ix